Rubius Therapeutics (NASDAQ: RUBY) reported Q2 EPS of ($0.50), $0.05 worse than the analyst estimate of ($0.45).“During the second quarter ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE